Table 1.
Baseline demographics and clinical characteristics
| Characteristic | Clodronate (n = 530) | Placebo (n = 539) |
| Mean age ± SD (years) | 52.8 ± 10.6 | 52.7 ± 10.5 |
| Mean BMI ± SD (kg/m2) | 25.8 ± 4.5 | 25.8 ± 4.8 |
| Menopausal status (n) | ||
| Premenopausal | 265 (50%) | 265 (49%) |
| Postmenopausal | 265 (50%) | 274 (51%) |
| Axillary lymph node involvement (n) | 196 (37%) | 202 (38%) |
| Tumor stage (n) | ||
| I | 137 (26%) | 143 (26%) |
| II | 304 (57%) | 305 (57%) |
| III | 48 (9%) | 52 (10%) |
| Unclassifiable | 40 (8%) | 39 (7%) |
| Missing | 1 (0.2%) | 0 (0%) |
| Hormone receptor status (n) | ||
| Oestrogen receptor-positive | 245 (46%) | 240 (45%) |
| Oestrogen receptor-negative | 136 (26%) | 136 (25%) |
| Oestrogen receptor-unknown | 149 (28%) | 163 (30%) |
| Progesterone receptor-positive | 112 (21%) | 116 (22%) |
| Progesterone receptor-negative | 79 (15%) | 75 (14%) |
| Progesterone receptor-unknown | 339 (64%) | 348 (65%) |
BMI, body mass index; SD, standard deviation.